MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock under the...
$6,737K
(188.28%↑ Y/Y)
Net cash provided by
financing activities
$6,610K
(222.75%↑ Y/Y)
Canceled cashflow
$127K
Net decrease in
cash, cash...
$3,537K
(126.29%↑ Y/Y)
Canceled cashflow
$3,073K
Payments on loan payable
$116K
(-51.26%↓ Y/Y)
Payment of employee
withholding taxes on vested...
$11K
(-78.43%↓ Y/Y)
Grant receivables
-$706K
(-119.62%↓ Y/Y)
Deferred grant income and
other liabilities
$557K
(-39.19%↓ Y/Y)
Prepaid expenses and
other assets
-$346K
(47.01%↑ Y/Y)
Equity-based compensation
$319K
(-73.57%↓ Y/Y)
Amortization of right-of-use
assets
$45K
(-54.55%↓ Y/Y)
Depreciation and
amortization
$10K
(42.86%↑ Y/Y)
Net cash used in
operating activities
-$3,053K
(80.30%↑ Y/Y)
Net cash used in
investing activities
-$20K
Canceled cashflow
$1,983K
Grant income
$3,518K
(-71.15%↓ Y/Y)
Other segment items
-$288K
(17.00%↑ Y/Y)
Net loss
-$3,932K
(74.16%↑ Y/Y)
Payments for property and
equipment
$20K
Canceled cashflow
$3,806K
Accounts payable and
accrued expenses
-$1,038K
(-292.58%↓ Y/Y)
Operating lease
liabilities
-$45K
(58.33%↑ Y/Y)
Gain on lease
modification
$21K
Clinical programs
$2,857K
(-81.02%↓ Y/Y)
General and
administrative expenses
$2,454K
R&d personnel costs
$1,758K
(-64.65%↓ Y/Y)
Equity-based compensation
$319K
(-73.57%↓ Y/Y)
Manufacturing
$246K
(-78.61%↓ Y/Y)
Preclinical programs
$63K
(-72.00%↓ Y/Y)
Other research and
development expenses
$41K
(-81.94%↓ Y/Y)
Back
Back
Cash Flow
COGNITION THERAPEUTICS INC (CGTX)
COGNITION THERAPEUTICS INC (CGTX)
source: myfinsight.com